Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: "The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. | Kim et al. Radiation Oncology 2010 5 75 http www.ro-journal.eom content 5 1 75 RADIATION ONCOLOGY RESEARCH Open Access The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis a retrospective study 112 2 3 3 Jun Won Kim Yong Bae Kim Nam-Kyu Kim Byung-Soh Min Sang Joon Shin Joong Bae Ahn Woong Sub Koom1 Jinsil Seong1 Ki Chang Keum1 Abstract Background Synchronous liver metastases are detected in approximately 25 of colorectal cancer patients at diagnosis. The rates of local failure and distant metastasis are substantial in these patients even after undergoing aggressive treatments including resection of primary and metastatic liver tumors. The purpose of this study was to determine whether adjuvant pelvic radiotherapy is beneficial for pelvic control and overall survival in rectal cancer patients with synchronous liver metastasis after primary tumor resection. Methods Among rectal cancer patients who received total mesorectal excision TME between 1997 and 2006 at Yonsei University Health System eighty-nine patients diagnosed with synchronous liver metastasis were reviewed. Twenty-seven patients received adjuvant pelvic RT group S R and sixty-two patients were managed without RT group S . Thirty-six patients 58 in group S and twenty patients 74 in group S R received local treatment for liver metastasis. Failure patterns and survival outcomes were analyzed. Results Pelvic failure was observed in twenty-five patients twenty-one patients in group S 34 and four patients in group S R 15 p 0.066 . The two-year pelvic failure-free survival rates PFFS of group S and group S R were 64.8 and 80.8 p 0.028 respectively and the two-year overall survival rates OS were 49.1 and 70.4 p 0.116 respectively. In a subgroup analysis of fifty-six patients who received local treatment for liver metastasis the two-year PFFS were 64.9 and 82.9 p 0.05 respectively the two-year OS were 74.1 and 80.0 p 0.616 in group S n 36 and group S R n 20 respectively. .